Alder Biopharmaceuticals Inc ALDR:NASDAQ

Last Price$18.92NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/18/19

Today's Change0(0.00%)
Bid (Size)$17.30 (5)
Ask (Size)$19.05 (3)
Day Low / HighN/A - N/A
Volume7.4 M

View Biotechnology IndustryPeer Comparison as of 10/18/2019


Alder Biopharmaceuticals Inc ( NASDAQ )

Price: $18.92
Change: +0.02 (0.11%)
Volume: 7.4 M
4:00PM ET 10/18/2019

Aimmune Therapeutics Inc ( NASDAQ )

Price: $25.15
Change: -0.14 (0.55%)
Volume: 443.0 K
4:00PM ET 10/18/2019

Insmed Inc ( NASDAQ )

Price: $17.42
Change: 0.00 (0.00%)
Volume: 704.6 K
4:00PM ET 10/18/2019

Heron Therapeutics Inc ( NASDAQ )

Price: $18.45
Change: -0.16 (0.83%)
Volume: 1.1 M
4:00PM ET 10/18/2019

Deciphera Pharmaceuticals Inc ( NASDAQ )

Price: $34.26
Change: +0.03 (0.09%)
Volume: 277.7 K
3:59PM ET 10/18/2019

Read more news Recent News

Alder BioPharmaceuticals Begins Phase 1 Study of Migraine Treatment ALD1910
8:34AM ET 10/10/2019 MT Newswires

Alder BioPharmaceuticals (ALDR) said Thursday it has dosed the first patient in a phase 1 clinical study to evaluate ALD1910 as a preventive treatment for...

--Analyst Actions: Wells Fargo Lowers Price Target For Alder BioPharmaceuticals to $30 From $36, Maintains Outperform Rating
12:06PM ET 9/17/2019 MT Newswires

Price: 18.75, Change: +0.25, Percent Change: +1.35 ...

--Analyst Actions: SVB Leerink Downgrades Alder BioPharmaceuticals to Market Perform From Outperform, PT Lowered to $20 From $21
12:05PM ET 9/17/2019 MT Newswires

Price: 18.71, Change: +0.21, Percent Change: +1.14 ...

--Analyst Actions: Cantor Fitzgerald Raises Alder BioPharmaceuticals Price Target to $18 From $14, Maintains Neutral Rating
12:02PM ET 9/17/2019 MT Newswires

Price: 18.70, Change: +0.20, Percent Change: +1.09 ...

Company Profile

Business DescriptionAlder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. View company web site for more details
Address11804 North Creek Parkway South
Bothell, Washington 98011
Number of Employees202
Recent SEC Filing10/17/2019SC TO-T/A
President, Chief Executive Officer & DirectorRobert W. Azelby
Chief Operating OfficerErin Lavelle
Chief Financial OfficerCarlos E. Campoy
Chief Medical OfficerPaul Streck

Company Highlights

Price Open$18.88
Previous Close$18.90
52 Week Range$8.39 - 18.99
Market Capitalization$1.6 B
Shares Outstanding83.8 M
SectorHealth Technology
Next Earnings Announcement11/04/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.44
Beta vs. S&P 500N/A
Net Profit MarginN/A
Return on Equity-129.99%

Analyst Ratings as of 09/16/2019

Consensus RecommendationConsensus Icon
Powered by Factset